

OMALIZUMAB REQUEST FORM

PATIENT DETAILS					
Patient's Name and Surname: _____					
Date of Birth: _____	I.D. Card No: _____				
Address: _____					
Age: _____	Tel/Mob No: _____				
SECTION A					
Schedule V Condition: <input type="checkbox"/> Chronic Asthma					
SECTION B (New Patients)					
Omalizumab should be reserved for patients meeting ALL the following criteria:					
<input type="checkbox"/>	Used as add-on therapy for severe persistent asthma that remains inadequately controlled despite best available therapy				
<input type="checkbox"/>	Patient has IgE Mediated Asthma with IgE levels ≥ 76 IU/mL in adults and adolescents, or ≥ 200 IU/mL in children (6-12 years). If IgE levels are less than these values, an unequivocal in vitro reactivity (RAST) to a perennial allergen is required. (Test result/s must be attached)				
<input type="checkbox"/>	Patient has a positive skin test or in vitro reactivity to a perennial aeroallergen. (Test result must be attached)				
<input type="checkbox"/>	Reduced lung function (FEV ₁ <80%)				
<input type="checkbox"/>	Frequent daytime symptoms or night-time awakenings				
<input type="checkbox"/>	Multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta ₂ –agonist.				
SECTION C (Renewal after 16 weeks of treatment)					
After 16 weeks of commencing omalizumab therapy, patients should be assessed for treatment effectiveness before further injections are administered. Renewal of treatment will only be approved if patient meets ALL the following criteria:					
<input type="checkbox"/>	Patient is compliant with the treatment				
<input type="checkbox"/>	Marked improvement in overall asthma control is seen				
SECTION D (Renewal after 12 months of treatment and other further renewals)					
Renewal of treatment will only be approved if patient meets ALL the following criteria:					
<input type="checkbox"/>	Patient is compliant with the treatment				
<input type="checkbox"/>	Patient is benefitting from the treatment				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; vertical-align: bottom;">Signature of Consultant</td> <td style="width: 50%; border-bottom: 1px solid black; vertical-align: bottom;">Name in Block Letters and Medical Council Reg. Number</td> </tr> <tr> <td style="width: 50%; border-bottom: 1px solid black; vertical-align: bottom;">Date</td> <td style="width: 50%; border-bottom: 1px solid black; vertical-align: bottom;">Countersignature by Clinical Chairman Paediatrics or Lead Consultant Respiratory Physician</td> </tr> </table>		Signature of Consultant	Name in Block Letters and Medical Council Reg. Number	Date	Countersignature by Clinical Chairman Paediatrics or Lead Consultant Respiratory Physician
Signature of Consultant	Name in Block Letters and Medical Council Reg. Number				
Date	Countersignature by Clinical Chairman Paediatrics or Lead Consultant Respiratory Physician				
For office use only: <div style="float: right; text-align: right;"> Approved <input type="checkbox"/> Not Approved <input type="checkbox"/> </div>					
_____ Pharmacist's Signature	_____ Name in Block Letters	_____ Date			

Kindly fill ALL required sections

Data Protection Statement

All personal data is required to provide you with health care services as necessary, and is processed in accordance with the Data Protection Act, and as permitted by law. Further information about your data can be obtained on request.